Indeed, a phase II dose-finding trial demonstrated greater body weight reductions associated with daily subcutaneous semaglutide at a dose greater than 0.2 mg compared with liraglutide 3.0 mg daily [35]
In terms of side effects, they are both similar in the type of side effects they can cause
Interestingly, a study that did implement this titration approach found during the maintenance phase, rats treated with semaglutide showed a unexpected marked increase in the intake of lower concentrations of sucrose compared to vehicle treated controls, despite continuing to consume chow at only 90% the level of vehicle-treated animals ( In line with clinical data, GLP-1R agonism may also directly influence food preference through modulation of taste receptor expression
A team of researchers from the University of Iowa has unveiled concerns about the use of semaglutide, a widely prescribed GLP-1 receptor agonist for type 2 diabetes and obesity, in patients with neuroendocrine neoplasms (NENs)
10.1007/s00221-010-2171-0 68